Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database


30 Sep 2019


Poster Display session 3


Tumour Site

Prostate Cancer


Junru Chen


Annals of Oncology (2019) 30 (suppl_5): v325-v355. 10.1093/annonc/mdz248


J. Chen1, Z. Wang1, J. Zhao1, S. Zhu1, G. Sun1, J. Liu1, H. Zhang1, X. Zhang1, P. Shen2, H. Zeng1

Author affiliations

  • 1 Urology, West China Hospital, Sichuan University, 610041 - Chengdu/CN
  • 2 Urology, West China Hospital, 610041 - Chengdu/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4695


The aim of the study was to evaluate the therapeutic role of pelvic lymph node dissection (PLND) and its extent in North American patients with a risk of lymph node invasion (LNI)>5%.


Data of 20,668 patients treated with radical prostatectomy (RP) with and without PLND from SEER database between 2010 and 2015 were retrospectively analyzed. All patients had a risk of LNI>5% according to 2012-Briganti nomogram. Propensity score matching (PSM) was performed to balance baseline characteristics between patients with and without PLND. Kaplan-Meier curves and Cox regression were used to evaluate the impacts of the PLND and its extent on cancer-specific survival (CSS) and overall survival (OS).


The median follow-up was 32 months. In overall cohort, patients with PLND were associated with more aggressive clinicopathologic characteristics and had poorer survival compared to those without PLND (5-year CSS rate: 98.4% vs. 99.7%, p < 0.001; 5-year OS rate: 96.3% vs. 97.8%, p < 0.001). PSM resulted in 4,267 patients in each group. In the post-PSM cohort, no significant difference in survival was found between patients with and without PLND (5-year CSS rate: 99.4% vs. 99.7%, p = 0.479; 5-year OS rate: 97.3% vs. 97.8%, p = 0.204). In addition, the extent of PLND had no impact on prognosis (all p < 0.05). Subgroup analyses reported similar negative findings.


Neither PLND nor its extent was associated with survival in North American patients with a risk of LNI>5%.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Hao Zeng.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.